BRAFV600E, KRAS G12C, and G13D mutations are linked to shorter survival after recurrence (SAR) in patients who underwent surgery for stage III microsatellite stable (MSS) colon cancer. This evidence concerns the gene KRAS and malignant colon neoplasm.